Zacks Research Upgrades Inspire Medical Systems (NYSE:INSP) to “Strong-Buy”

Inspire Medical Systems (NYSE:INSP) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other research analysts also recently weighed in on INSP. Stifel Nicolaus set a $75.00 price target on Inspire Medical Systems in a report on Tuesday, August 4th. JPMorgan Chase & Co. lifted their price target on Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Mizuho boosted their target price on shares of Inspire Medical Systems from $55.00 to $65.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $60.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Finally, Oppenheimer upgraded shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price target on the stock in a report on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Inspire Medical Systems has a consensus rating of “Hold” and a consensus price target of $66.19.

Inspire Medical Systems Stock Performance

INSP opened at $57.43 on Monday. The company has a market cap of $1.66 billion, a price-to-earnings ratio of 12.43, a PEG ratio of 4.34 and a beta of 0.70. Inspire Medical Systems has a one year low of $38.91 and a one year high of $147.03. The business’s fifty day moving average is $49.98 and its two-hundred day moving average is $52.92.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.38. The business had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company’s quarterly revenue was down 7.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, analysts predict that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, insider Jason P. Kelly sold 963 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider owned 18,985 shares of the company’s stock, valued at $1,130,556.75. This trade represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Inspire Medical Systems

Institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada increased its position in shares of Inspire Medical Systems by 16.0% during the 1st quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock valued at $5,220,000 after purchasing an additional 4,528 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of Inspire Medical Systems in the first quarter valued at $524,000. Goldman Sachs Group Inc. boosted its stake in Inspire Medical Systems by 57.9% during the first quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after buying an additional 18,857 shares in the last quarter. Marshall Wace LLP boosted its stake in Inspire Medical Systems by 3.8% during the second quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock valued at $2,064,000 after buying an additional 577 shares in the last quarter. Finally, Jump Financial LLC acquired a new position in Inspire Medical Systems during the second quarter worth about $931,000. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.